On Nov 27, major Wall Street analysts update their ratings for $Amgen (AMGN.US)$, with price targets ranging from $305 to $380.
Morgan Stanley analyst Terence Flynn maintains with a hold rating, and maintains the target price at $322.
Goldman Sachs analyst Salveen Richter maintains with a buy rating, and sets the target price at $375.
BofA Securities analyst Charlie CY Yang maintains with a hold rating, and maintains the target price at $335.
Deutsche Bank analyst James Shin maintains with a hold rating, and adjusts the target price from $285 to $305.
Wells Fargo analyst Mohit Bansal maintains with a hold rating, and maintains the target price at $335.
Furthermore, according to the comprehensive report, the opinions of $Amgen (AMGN.US)$'s main analysts recently are as follows:
MariTide's Phase II topline data displayed efficacy which met established expectations by showing up to 20% weight loss at week 52, though it was on the lower end of predictions. The possibility of monthly or less frequent dosing to enhance weight maintenance and durability could set it apart from existing and emerging therapeutics. However, there are ongoing questions regarding tolerability and the future treatment protocol. Despite these concerns, the overall profile of MariTide in treating obesity is considered a work-in-progress, yet the outlook on the company remains positive.
Here are the latest investment ratings and price targets for $Amgen (AMGN.US)$ from 11 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
